Advertisement


Andreas Burchert, MD, on AML: Results From the Sormain Trial

2018 ASH Annual Meeting & Exposition

Advertisement

Andreas Burchert, MD, of the Philipps University of Marburg, discusses study findings on sorafenib as maintenance therapy after allogeneic stem cell transplantation for FLT3-ITD–positive acute myeloid leukemia.



Related Videos

Skin Cancer
Lymphoma

Steven M. Horwitz, MD, on PTCL and CTCL: Trial Results on Cerdulatinib

Steven M. Horwitz, MD, of Memorial Sloan Kettering Cancer Center, discusses phase IIa study findings on the novel SYK/JAK inhibitor cerdulatinib for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma (Abstract 1001).

Immunotherapy
Lymphoma

Julie Vose, MD, MBA, and Loretta J. Nastoupil, MD, on Large B-Cell Lymphoma: Real-World Experience With CAR T-Cell Therapy

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and Loretta J. Nastoupil, MD, of The University of Texas MD Anderson Cancer Center, discuss findings from a multicenter study of axicabtagene ciloleucel CD19 CAR T-cell therapy for relapsed or refractory aggressive B-cell lymphoma when used as a standard of care (Abstract 91).

Issues in Oncology

Norman E. Sharpless, MD: Director of the National Cancer Institute: Articulating a Vision

Norman E. Sharpless, MD, Director of the National Cancer Institute, discusses his vision for the NCI in four key areas––big data, clinical trials, workforce development, and basic science––and how this vision affects the hematology community.

Leukemia
Immunotherapy

Saar I. Gill, MD, PhD, on CLL: Trial Results on Anti-CD19 CAR T Cells

Saar I. Gill, MD, PhD, of the University of Pennsylvania, discusses findings from a prospective clinical trial on the high response rate in patients with chronic lymphocytic leukemia who received a combination therapy of CAR T cells plus ibrutinib (Abstract 298).

Lymphoma

Steven M. Horwitz, MD, on PTCL: Results From the ECHELON-2 Trial

Steven M. Horwitz, MD, of Memorial Sloan Kettering Cancer Center, discusses phase III findings on brentuximab vedotin and CHP vs CHOP in the front-line treatment of patients with CD30-positive peripheral T-cell lymphomas (Abstract 997).

Advertisement

Advertisement




Advertisement